KBI Biopharma
Leslie Wolfe
VP of Process Development & Site Head
Learn how KBI Biopharma’s SUREtechnology Platform™, powered by Selexis®, combines refined project workflows to accelerate the development of complex biologics, from optimized cell line generation to rapid transitions to toxicology studies—all paving the way to First-in-Human trials.
Overview
This webinar focuses on how KBI Biopharma's SUREtechnology Platform™, powered by Selexis®, enables rapid advancement of new complex biologics from early development to first-in-human (FIH). Emphasizing both the speed and quality, the discussion will cover:
- Optimized Cell Line Development: How the integration of the SUREtechnology Platform™ accelerates the creation of high-performing, stable cell lines tailored for biologics production.
- Transposase and Versatility: Insights into the platform’s modular workflows and advanced transposase technology, which allows for highly efficient gene insertion, enabling increased clones performance consistency, further reducing cell line development bottlenecks.
- Streamlined Path to Toxicology Studies: A step-by-step breakdown of the streamlined process that minimizes time to reach preclinical toxicology milestones, emphasizing rapid transitions from cell line development to tox studies.
- Speed to FIH: How KBI Biopharma’s unique capabilities enable a significantly faster path to first-in-
human studies, ensuring customers can achieve clinical milestones with confidence.
Presenters
Shaunak Uplekar
Associate Director of Process Development
Let's Connect
Interested in learning more about KBI Biopharma? Contact us today.